Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108803
Title:
Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.
Authors:
Chopra, R; Goldstone, A H; McMillan, A K; Powles, R; Smith, A G; Prentice, H G; Reid, C; Marcus, R; Bell, A; Milligan, D; Morgenstern, Godfrey R; Barnard, D
Abstract:
The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis (four patients; one fatal), intracranial hemorrhage (two patients; two fatal) has occurred. There have been four procedure-related deaths (12%). Hematologic recovery was satisfactory for neutrophils (median time to 0.5 x 10(9)/L, 22 days [range, 11 to 101 days]), but very slow for platelets (median time to 50 x 10(9)/L, 62 days [range, 15 to 1,080 days]). This study suggests that the use of Bu/Cy with ABMT for patients beyond first remission in AML compares favorably with chemotherapy, and although the procedure-related mortality is acceptable, it is associated with protracted platelet recovery.
Affiliation:
University College and Middlesex Schools of Medicine, London, England.
Citation:
Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. 1991, 9 (10):1840-7 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
Oct-1991
URI:
http://hdl.handle.net/10541/108803
PubMed ID:
1919634
Type:
Article
Language:
en
ISSN:
0732-183X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorChopra, Ren
dc.contributor.authorGoldstone, A Hen
dc.contributor.authorMcMillan, A Ken
dc.contributor.authorPowles, Ren
dc.contributor.authorSmith, A Gen
dc.contributor.authorPrentice, H Gen
dc.contributor.authorReid, Cen
dc.contributor.authorMarcus, Ren
dc.contributor.authorBell, Aen
dc.contributor.authorMilligan, Den
dc.contributor.authorMorgenstern, Godfrey Ren
dc.contributor.authorBarnard, Den
dc.date.accessioned2010-08-02T10:33:11Z-
dc.date.available2010-08-02T10:33:11Z-
dc.date.issued1991-10-
dc.identifier.citationSuccessful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. 1991, 9 (10):1840-7 J. Clin. Oncol.en
dc.identifier.issn0732-183X-
dc.identifier.pmid1919634-
dc.identifier.urihttp://hdl.handle.net/10541/108803-
dc.description.abstractThe results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis (four patients; one fatal), intracranial hemorrhage (two patients; two fatal) has occurred. There have been four procedure-related deaths (12%). Hematologic recovery was satisfactory for neutrophils (median time to 0.5 x 10(9)/L, 22 days [range, 11 to 101 days]), but very slow for platelets (median time to 50 x 10(9)/L, 62 days [range, 15 to 1,080 days]). This study suggests that the use of Bu/Cy with ABMT for patients beyond first remission in AML compares favorably with chemotherapy, and although the procedure-related mortality is acceptable, it is associated with protracted platelet recovery.en
dc.language.isoenen
dc.subjectMyeloid Leukaemiaen
dc.subject.meshAcute Disease-
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshBusulfan-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCyclophosphamide-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLeukemia, Myeloid-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRemission Induction-
dc.subject.meshSurvival Analysis-
dc.subject.meshTransplantation, Autologous-
dc.titleSuccessful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.en
dc.typeArticleen
dc.contributor.departmentUniversity College and Middlesex Schools of Medicine, London, England.en
dc.identifier.journalJournal of Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.